drugset / Trial / NCT04405323
Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women
RandomizedSequentialOpen-labelTreatment
Summary
A study to learn how a drug (itraconazole) that is known to inhibit a certain enzym in the liver, impacts the body's ability to breakdown Lu AG06466 into breakdown products in healthy men and women. The main breakdown product is Lu AG06988.
Timeline
- Start
- 2020-05-20
- Primary completion
- 2020-07-28
- Completion
- 2020-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Itraconazole | Small molecule | 300 mg | Oral |
| Subject | Lu AG06466 | Unknown | — | Oral |
Indications
No indication recorded.